Intelliseq

About Intelliseq

Intelliseq, founded in 2014 in Krakow, Poland, operates in the field of genomic data analysis. The company was established by a team of academics from the Jagiellonian University, including Dr. Klaudia Szklarczyk-Smolana, Marcin Piechota, and Dr. hab. Pawel F. Góra, who brought their expertise in bioinformatics, molecular biology, and software development to the venture. Their academic background in genetics and bioinformatics provided a strong foundation for addressing challenges in Next-Generation Sequencing (NGS) data interpretation.

Intelliseq focuses on the automated interpretation of human DNA sequences, providing solutions for tertiary and quaternary genomic data analysis. The company's primary offering is the Intelliseq FLOW platform, an automated, cloud-based solution designed for raw genetic data analysis. This platform enables users to upload genomic data and receive detailed clinical reports, facilitating the diagnostic process for hereditary diseases. It processes data from whole genome, whole exome, and large gene panel sequencing. The service is targeted towards a range of clients, including diagnostic laboratories, hospitals, clinics, and scientific research institutions.

The business model centers on a fee-for-service or Software as a Service (SaaS) structure, where clients pay for the analysis of each genetic sample processed through the platform. Intelliseq's technology aims to streamline the complex process of NGS data analysis, reducing the time and manual effort required to move from raw data to an actionable clinical report. The platform is built on workflow standards like WDL and CWL and is available on various cloud platforms, including AWS, Google Cloud, and Azure. Key features of their service include VCF file annotation, gene prioritization, and the generation of comprehensive reports that aid in clinical decision-making. By automating the interpretation process, Intelliseq helps to make genomic medicine more accessible and efficient for its clients in the healthcare and research sectors.